دورية أكاديمية
أعرض في EDS

Engineering approaches for studying immune-tumor cell interactions and immunotherapy.

التفاصيل البيبلوغرافية
العنوان: Engineering approaches for studying immune-tumor cell interactions and immunotherapy.
المؤلفون: Shelton SE; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA., Nguyen HT; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Barbie DA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Kamm RD; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
المصدر: IScience [iScience] 2020 Dec 23; Vol. 24 (1), pp. 101985. Date of Electronic Publication: 2020 Dec 23 (Print Publication: 2021).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Cambridge, MA] : Cell Press, [2018]-
مستخلص: This review describes recent research that has advanced our understanding of the role of immune cells in the tumor microenvironment (TME) using advanced 3D in vitro models and engineering approaches. The TME can hinder effective eradication of tumor cells by the immune system, but immunotherapy has been able to reverse this effect in some cases. However, patient-to-patient variability in response suggests that we require deeper understanding of the mechanistic interactions between immune and tumor cells to improve response and develop novel therapeutics. Reconstruction of the TME using engineered 3D models allows high-resolution observation of cell interactions while allowing control of conditions such as hypoxia, matrix stiffness, and flow. Moreover, patient-derived organotypic models are an emerging tool for prediction of drug efficacy. This review highlights the importance of modeling and understanding the immune TME and describes new tools for identifying new biological targets, drug testing, and strategies for personalized medicine.
Competing Interests: RDK is a co-founder and has a significant financial interest in AIM Biotech, a company that manufactures microfluidic systems and has received research funding from Elstar, 10.13039/100002429Amgen and 10.13039/100005614Biogen. DAB is an inventor on patents related on manipulating, culturing, and evaluating tumor spheroids. DAB is a consultant for N of One and Tango Therapeutics, has received honoraria from Loxo Oncology and Madalon Consulting, research grants from 10.13039/100002491BMS, 10.13039/100004336Novartis, 10.13039/100004312Lilly, and 10.13039/100005564Gilead Sciences, and is a co-founder and on the scientific advisory board of Xsphera Biosciences Inc.
(© 2021 The Authors.)
References: Lab Chip. 2018 Jun 26;18(13):1844-1858. (PMID: 29796561)
Adv Healthc Mater. 2019 Jun;8(11):e1900289. (PMID: 31056856)
Cell. 2016 Mar 24;165(1):100-110. (PMID: 26924577)
Biochem Biophys Res Commun. 2018 Jan 8;495(2):1930-1935. (PMID: 29248729)
Front Physiol. 2014 Mar 05;5:75. (PMID: 24634660)
Clin Diagn Lab Immunol. 2000 Nov;7(6):859-64. (PMID: 11063487)
Cancer Res. 2017 Jan 15;77(2):279-290. (PMID: 27872091)
Eur J Cancer. 1997 Apr;33(4):645-51. (PMID: 9274449)
Biomed Microdevices. 2011 Oct;13(5):899-907. (PMID: 21739185)
Cancer Cell. 2020 Oct 12;38(4):473-488. (PMID: 32735779)
BMC Cancer. 2015 May 03;15:351. (PMID: 25933805)
Br J Cancer. 2004 Nov 1;91(9):1711-7. (PMID: 15494715)
Nat Rev Cancer. 2019 Feb;19(2):65-81. (PMID: 30647431)
Sci Rep. 2014 Oct 16;4:6639. (PMID: 25322144)
Nat Rev Mol Cell Biol. 2006 Mar;7(3):211-24. (PMID: 16496023)
Lab Chip. 2018 Dec 4;18(24):3733-3749. (PMID: 30397689)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Biomaterials. 2019 Apr;198:180-193. (PMID: 29548546)
Oncoimmunology. 2013 Dec 1;2(12):e26860. (PMID: 24498559)
ACS Appl Mater Interfaces. 2019 Oct 16;11(41):37513-37523. (PMID: 31547654)
Cancer Immunol Res. 2017 Nov;5(11):950-956. (PMID: 28963140)
Adv Healthc Mater. 2012 Sep;1(5):590-9. (PMID: 23184794)
Front Immunol. 2020 May 07;11:784. (PMID: 32457745)
Genes Dev. 2018 Oct 1;32(19-20):1267-1284. (PMID: 30275043)
Am J Transplant. 2010 Mar;10(3):637-45. (PMID: 20121725)
Lab Chip. 2018 Oct 9;18(20):3129-3143. (PMID: 30183789)
J Biotechnol. 2015 Jul 10;205:14-23. (PMID: 25746901)
RSC Adv. 2013 Sep 28;3(36):16002-16010. (PMID: 29682279)
Br J Cancer. 2007 Apr 10;96(7):1072-82. (PMID: 17342088)
J Immunol Methods. 2015 Nov;426:1-13. (PMID: 26215372)
Trends Cell Biol. 2011 Dec;21(12):745-54. (PMID: 22033488)
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):992-997. (PMID: 29343642)
J Immunol. 2018 Feb 15;200(4):1255-1260. (PMID: 29330322)
Int J Biol Sci. 2011;7(5):651-8. (PMID: 21647333)
Cancer Res. 2017 Oct 1;77(19):5215-5221. (PMID: 28928130)
Adv Sci (Weinh). 2020 Nov 03;7(24):2002628. (PMID: 33344135)
Lab Chip. 2006 Nov;6(11):1462-9. (PMID: 17066171)
Semin Immunol. 2018 Feb;35:29-34. (PMID: 29428698)
Oncoimmunology. 2018 Dec 12;8(3):1553477. (PMID: 30723584)
J Cell Physiol. 2019 Jun;234(6):8509-8521. (PMID: 30520029)
Cell. 2020 Jan 9;180(1):188-204.e22. (PMID: 31883794)
Biomaterials. 2020 Sep;252:120058. (PMID: 32413594)
Nat Biomed Eng. 2019 Oct;3(10):830-841. (PMID: 31427781)
Converg Sci Phys Oncol. 2017;3:. (PMID: 30079253)
Biomaterials. 2018 Apr;161:164-178. (PMID: 29421553)
Cell. 2007 Aug 24;130(4):601-10. (PMID: 17719539)
Sci Rep. 2017 Oct 6;7(1):12737. (PMID: 28986543)
Mol Biol Cell. 2018 Aug 8;29(16):1927-1940. (PMID: 29995595)
Regen Eng Transl Med. 2018 Sep;4(3):120-132. (PMID: 30417074)
BMC Med. 2016 May 05;14:73. (PMID: 27151159)
Adv Funct Mater. 2020 Nov 25;30(48):. (PMID: 33692661)
Int J Cancer. 2002 Mar 1;98(1):51-6. (PMID: 11857385)
Cancer Immunol Immunother. 2017 Jan;66(1):129-140. (PMID: 27858101)
Sci Transl Med. 2019 Oct 9;11(513):. (PMID: 31597751)
Nano Lett. 2017 Feb 8;17(2):821-826. (PMID: 28122453)
Cell. 2015 May 7;161(4):933-45. (PMID: 25957691)
Adv Healthc Mater. 2019 Aug;8(15):e1900754. (PMID: 31393091)
Nat Rev Clin Oncol. 2012 Apr 17;9(6):338-50. (PMID: 22508028)
Cancer Res. 2020 Jan 1;80(1):44-56. (PMID: 31662325)
Lab Chip. 2019 Mar 13;19(6):1013-1026. (PMID: 30742147)
Adv Drug Deliv Rev. 2019 Feb 1;140:68-77. (PMID: 29944904)
Front Immunol. 2018 Mar 06;9:416. (PMID: 29559973)
Cell. 2018 Sep 6;174(6):1586-1598.e12. (PMID: 30100188)
Analyst. 2012 Sep 7;137(17):4062-8. (PMID: 22822477)
Front Immunol. 2020 Sep 04;11:2090. (PMID: 33013881)
Integr Biol (Camb). 2020 Apr 20;12(4):90-108. (PMID: 32248236)
Nat Rev Clin Oncol. 2017 Mar;14(3):187-192. (PMID: 27995946)
Adv Sci (Weinh). 2019 Apr 10;6(11):1900195. (PMID: 31179226)
Biotechnol Bioeng. 2019 Jul;116(7):1731-1741. (PMID: 30802293)
BMC Cancer. 2018 Mar 27;18(1):335. (PMID: 29587663)
Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):7022-7027. (PMID: 29915060)
Cancer Discov. 2018 Sep;8(9):1112-1129. (PMID: 29853643)
Sci Rep. 2017 Apr 24;7(1):1093. (PMID: 28439087)
Integr Biol (Camb). 2012 Feb;4(2):177-82. (PMID: 22179425)
Adv Healthc Mater. 2020 Apr;9(8):e1901410. (PMID: 31994845)
Adv Biosyst. 2018 Feb;2(2):. (PMID: 31008184)
J Gastroenterol. 2016 Mar;51(3):206-13. (PMID: 26800996)
JCI Insight. 2017 Jun 15;2(12):. (PMID: 28614795)
Lab Chip. 2016 Oct 7;16(19):3728-40. (PMID: 27560793)
Lab Chip. 2013 Jan 21;13(2):229-39. (PMID: 23108434)
Oncotarget. 2015 Nov 17;6(36):39196-210. (PMID: 26474279)
Nat Rev Drug Discov. 2019 Mar;18(3):197-218. (PMID: 30610226)
Sci Rep. 2018 Feb 13;8(1):2886. (PMID: 29440675)
Nat Commun. 2020 Jan 14;11(1):259. (PMID: 31937780)
Cancer Res. 2020 Jan 15;80(2):263-275. (PMID: 31744818)
Nature. 2019 Sep;573(7772):69-74. (PMID: 31435009)
Sci Rep. 2016 Dec 19;6:39190. (PMID: 27991524)
J Immunotoxicol. 2014 Oct;11(4):337-46. (PMID: 24597645)
Lab Chip. 2015 Aug 7;15(15):3222-31. (PMID: 26126574)
Cancers (Basel). 2020 Mar 20;12(3):. (PMID: 32245016)
Biomacromolecules. 2013 May 13;14(5):1330-7. (PMID: 23517456)
Oncotarget. 2017 Aug 5;8(40):66747-66757. (PMID: 28977993)
JCI Insight. 2019 Sep 19;4(18):. (PMID: 31415244)
Cancer Discov. 2018 Feb;8(2):196-215. (PMID: 29101162)
Oncotarget. 2015 Sep 22;6(28):25295-307. (PMID: 26231039)
Front Immunol. 2018 Apr 23;9:857. (PMID: 29740450)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Nat Rev Cancer. 2017 Aug 24;17(9):569. (PMID: 28835723)
Cancer Discov. 2018 Nov;8(11):1358-1365. (PMID: 30309862)
Adv Healthc Mater. 2019 Mar;8(5):e1900001. (PMID: 30734529)
Clin Cancer Res. 2020 May 15;26(10):2393-2403. (PMID: 32034078)
Cell. 2018 Dec 13;175(7):1972-1988.e16. (PMID: 30550791)
Mol Cancer Ther. 2017 Nov;16(11):2598-2608. (PMID: 28835386)
Nat Commun. 2019 Sep 5;10(1):3991. (PMID: 31488816)
Cell Res. 2020 Jun;30(6):507-519. (PMID: 32467593)
Cancer Discov. 2019 Jan;9(1):34-45. (PMID: 30297358)
Front Cell Dev Biol. 2016 Jun 23;4:64. (PMID: 27446916)
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13515-20. (PMID: 22869695)
Cells. 2019 Oct 27;8(11):. (PMID: 31717887)
Oncogene. 2016 Oct 6;35(40):5263-5271. (PMID: 26996663)
معلومات مُعتمدة: K00 CA212227 United States CA NCI NIH HHS; U01 CA214381 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: Bioengineering; Cancer; Components of the Immune System
تواريخ الأحداث: Date Created: 20210125 Latest Revision: 20240805
رمز التحديث: 20240805
مُعرف محوري في PubMed: PMC7808917
DOI: 10.1016/j.isci.2020.101985
PMID: 33490895
قاعدة البيانات: MEDLINE
الوصف
تدمد:2589-0042
DOI:10.1016/j.isci.2020.101985